LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC.J Immunother Cancer | PMID 39721752PMC11683914 | 2024-Dec-25 | 0.90 | While the record is from a Phase III randomized trial with a drug intervention and original results, it does not report a primary or key secondary time-to-event efficacy endpoint. The analysis is a biomarker study focused on T-cell diversity and its association with response/toxicity, not a Kaplan-Meier or hazard ratio analysis of survival or progression-free survival. | 待处理 |
| Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.Signal Transduct Target Ther | PMID 39715755PMC11666711 | 2024-Dec-24 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up).Br J Dermatol | PMID 39438067无 PMCID | 2024-Dec-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pharmacokinetic-pharmacodynamic Modelling of NH600001 in Healthy Subjects and Patients Undergoing Gastroscopy.AAPS J | PMID 39707020无 PMCID | 2024-Dec-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study.Arthritis Res Ther | PMID 39709462PMC11662803 | 2024-Dec-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.J Clin Oncol | PMID 39279580PMC11654448 | 2024-Dec-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39292975无 PMCID | 2024-Dec-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.J Clin Oncol | PMID 39361946PMC11652233 | 2024-Dec-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 部分完成 |
| Sexual health and healthy relationships for Further Education (SaFE) in Wales and England: results from a pilot cluster randomised controlled trial.BMJ Open | PMID 39806667PMC11667339 | 2024-Dec-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| General practitioner advance care planning knowledge and attitudes: ACP-GP cluster-randomised controlled trial.BMJ Support Palliat Care | PMID 38925875无 PMCID | 2024-Dec-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype.N Engl J Med | PMID 39248309无 PMCID | 2024-Dec-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis in Vietnam.N Engl J Med | PMID 39693541无 PMCID | 2024-Dec-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Levofloxacin Preventive Treatment in Children Exposed to MDR Tuberculosis.N Engl J Med | PMID 39693542无 PMCID | 2024-Dec-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer.J Patient Rep Outcomes | PMID 39694978PMC11655800 | 2024-Dec-19 | 0.90 | The publication is from a Phase 3 randomized trial (LIBRETTO-531) in oncology and humans, but it is a psychometric analysis of a patient-reported tolerability measure (GP5). It does not report any survival, progression, recurrence, death, hazard, or time-to-event efficacy outcomes required for Kaplan-Meier digitization. | 待处理 |
| Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis.Arthritis Res Ther | PMID 39702318PMC11657006 | 2024-Dec-19 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine.J Clin Endocrinol Metab | PMID 38828555PMC11651685 | 2024-Dec-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study.Signal Transduct Target Ther | PMID 39690158PMC11652652 | 2024-Dec-18 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study.Blood Cancer J | PMID 39695117PMC11655548 | 2024-Dec-18 | 0.95 | Although the study meets many criteria (oncology, human, randomized, Phase 3, drug intervention, original results), it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). The primary endpoint is a categorical response (SVR35 at 24 weeks), and secondary endpoints are also categorical (best response rates, TSS50, anemia improvement). No time-to-event analysis is described or implied. | 待处理 |
| A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older (STRIDE-6).Clin Infect Dis | PMID 39082735PMC11650886 | 2024-Dec-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and Immunogenicity of an mRNA-1273 Booster in Children.Clin Infect Dis | PMID 39158584PMC11650855 | 2024-Dec-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection.Clin Infect Dis | PMID 39180325PMC11650871 | 2024-Dec-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Symptom Screening Linked to Care Pathways for Pediatric Patients With Cancer: A Randomized Clinical Trial.JAMA | PMID 39535768PMC11561721 | 2024-Dec-17 | 0.95 | The trial is a Phase III randomized clinical trial in pediatric oncology patients with original results, but it does not involve a drug-containing intervention (the intervention is a symptom screening and care pathway system) and does not have a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, or Kaplan-Meier/HR analysis. | 待处理 |
| Cytomegalovirus Antiviral Resistance Among Kidney Transplant Recipients in a Phase 3 Trial of Letermovir vs Valganciclovir Prophylaxis.J Infect Dis | PMID 38853607PMC11646593 | 2024-Dec-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials.J Infect Dis | PMID 39225478PMC11646576 | 2024-Dec-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III randomized trial comparing palliative systemic therapy to best supportive care in advanced esophageal/GEJ cancer.Int J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39093841无 PMCID | 2024-Dec-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy of Radicava® IV (intravenous edaravone) in subjects with differing trajectories of disease progression in amyotrophic lateral sclerosis: Use of a novel statistical approach for post hoc analysis of a pivotal phase 3 clinical trial.J Neurol Sci | PMID 39531940无 PMCID | 2024-Dec-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.Lancet | PMID 39581202无 PMCID | 2024-Dec-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment.N Engl J Med | PMID 39254740无 PMCID | 2024-Dec-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial.RMD Open | PMID 39672591PMC11647317 | 2024-Dec-12 | 0.95 | The study is a randomized Phase 3b trial with drug intervention and original results, but it investigates a non-oncology condition (psoriatic arthritis). Furthermore, the primary/key efficacy endpoints (ACR 20/50 response rates) are not time-to-event outcomes; no Kaplan-Meier or time-to-event analysis is reported. | 待处理 |
| AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients.Nat Commun | PMID 39663356PMC11634963 | 2024-Dec-11 | 0.75 | The record describes a secondary, biomarker-focused analysis (ctDNA detection) within a Phase III randomized trial. While it references the trial's drug intervention and OS endpoint, it is not the original primary efficacy report comparing intervention arms. It is a correlative/prognostic sub-study, which falls under the excluded 'post-hoc subgroup, biomarker-only' category for adjudication of primary trial KM data. | 待处理 |
| Pooled safety evaluation for a new single-shot live-attenuated chikungunya vaccine†.J Travel Med | PMID 39400050无 PMCID | 2024-Dec-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants: The PLUSS Randomized Clinical Trial.JAMA | PMID 39527075PMC11555571 | 2024-Dec-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.Inflamm Bowel Dis | PMID 38271613PMC11630349 | 2024-Dec-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.Inflamm Bowel Dis | PMID 38459910PMC11630283 | 2024-Dec-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.Blood疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39197072无 PMCID | 2024-Dec-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women.N Engl J Med | PMID 39216091PMC11711015 | 2024-Dec-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39282896无 PMCID | 2024-Dec-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Liposomal Bupivacaine Use in Third Molar Impaction Surgery: INNOVATE Study.Anesth Prog | PMID 39711449PMC11614472 | 2024-Dec-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bilastine 0.6% Preservative-Free Eye Drops as an Effective Once-Daily Treatment for the Signs and Symptoms of Allergic Conjunctivitis: A Pooled Analysis of 2 Randomized Clinical Trials.J Investig Allergol Clin Immunol | PMID 37732873无 PMCID | 2024-Dec-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Osilodrostat treatment in patients with Cushing's disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4).Endocr J | PMID 39183039PMC11778389 | 2024-Dec-02 | 0.95 | The study investigates osilodrostat for Cushing's disease, an endocrine disorder, not a human malignant neoplasm. It is not an oncology trial. | 待处理 |
| A randomized, active-controlled, multi-centric, phase-II clinical study to assess safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine (HEXASIIL®) in Indian toddlers.Vaccine | PMID 39303376无 PMCID | 2024-Dec-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study.Vaccine | PMID 39461302无 PMCID | 2024-Dec-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.Clin Cancer Res | PMID 39475359PMC11609623 | 2024-Dec-02 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 部分完成 |
| Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia: A Randomized Clinical Trial.JAMA Netw Open | PMID 39625722PMC11615712 | 2024-Dec-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group.Int J Radiat Oncol Biol Phys | PMID 38631539无 PMCID | 2024-Dec-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Dupilumab Improves Health-Related Quality of Life and a Range of Symptoms in Patients With Eosinophilic Esophagitis.Am J Gastroenterol | PMID 38940435PMC11608616 | 2024-Dec-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 Trial.Int J Radiat Oncol Biol Phys | PMID 38972465无 PMCID | 2024-Dec-01 | 0.95 | The trial is a randomized Phase III oncology study in humans with an original result, but it is excluded because the intervention is non-drug (radiation therapy techniques only) and the primary endpoint (freedom from failure at 2 years) is reported as a categorical outcome without time-to-event analysis (Kaplan-Meier, HR, or similar). | 待处理 |
| Acute Toxicity and Early Prostate Specific Antigen Response After Two-Fraction Stereotactic Radiation Therapy for Localized Prostate Cancer Using Peri-Rectal Spacing-Initial Report of the SABR-Dual Trial.Int J Radiat Oncol Biol Phys | PMID 39002849无 PMCID | 2024-Dec-01 | 0.95 | The record describes the initial report from the Phase I safety cohort of a Phase III trial. While the overall trial design is Phase III and randomized, this specific report is non-randomized and focuses on acute toxicity and quality of life endpoints, not a primary time-to-event efficacy endpoint (e.g., OS, PFS). Additionally, the intervention is radiation-based, not a drug-containing intervention. | 待处理 |
| Helical Tomotherapy Versus 3-Dimensional Conformal Radiation Therapy in High-Risk Prostate Cancer: A Phase 3 Randomized Controlled Trial.Int J Radiat Oncol Biol Phys | PMID 39009322无 PMCID | 2024-Dec-01 | 0.90 | The study is a Phase III randomized trial in oncology with a time-to-event endpoint (biochemical progression-free survival with HR), but the intervention under investigation is a radiation therapy technique, not a drug. The trial does not compare a drug-containing regimen against another; it compares two radiation delivery methods while both arms receive identical standard androgen deprivation therapy. Therefore, it lacks the required drug intervention for inclusion. | 待处理 |
| Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial.Am J Respir Crit Care Med | PMID 39012226PMC11622436 | 2024-Dec-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |